GLB1 and lysosomal storage disease: Inhibitors of β‐galactosidase have applications as therapeutics, such as being chaperones for therapy of lysosomal storage disorders[7,8] and as activity‐based probes.[9] Relevant lysosomal storage disorders include GM1‐gangliosidoses and Morquio B syndrome.[10,11] Lysosomal storage disorders are caused by a mutation of the GLB1 gene which codes for β‐galactosidase in humans, leading to a deficiency of functioning lysosomal enzymes.